Global Leader of Cancer Treatments


Product outline

ATB-301 is a new drug candidate for Combined anti-cancer treatment of
TGF-β selective inhibitor, TGF-β2 Targeting Antisense Oligonucleotide (ASO) and IL-2

TGF-β2 Targeting ASO
18-mer phosphorothioate ASO (Antisense-Oligo) nucleotide new drug targeting human TGF-β2
Designed based on the correlation between TGF-β overexpression and tumor progression
in-vitro/in-vivo/clinical efficacy data available on single therapies for pancreatic cancer, melanoma, glioblastoma
In-vitro test : Verified synergistic effect by TASO+IL-2 combination therapy on breast cancer cell line (SK-BR-3, MD-MB-231), Pancreatic cancer cell line (AsPC-1, HUP-T3), Lung cancer cell line (A549), Melanoma cell line (Hs294T, A2058), and Colorectal Cancer (LS174T, HT29).
In-vivo test : Verified synergistic effect by TASO +IL-2 combination therapy on humanized mouse (PBL-NSG mouse model) using TNBC (MDA-MB-231) and melanoma (A2058) xenograft model with TASO + IL-2

Pharmacological mechanism and evidence of combination therapy

  • Problem
    Immuno-oncology drugs are effective, but their response rate varies greatly upon cancer type
    TGF-β has been found to be the main cause of resistance to immuno-oncology drugs.
  • Solution
    Improving response rate in various cancer types by combined therapy
    Increasing treatment effect by using the substances inhibiting TGF-β

Combination therapy

Combined therapy

Pipeline expandability

TGF-β2 Targeting ASO combination therapy with PD-1/PD-L1 or CTLA-4 immuno-oncology ▶ ATB-302, 303

Pipeline expandability
New drug development of TGF-β2 Targeting ASO + Immunotherapy combination
  • Strong tumor suppression result by TGF-β2 Targeting ASO + Immune check point inhibitor combination therapy
  • In-vivo test with a global CRO for synergistic effect by the combined therapy of TGF-β2 Targeting ASO + IL-2 based on above in-vivo and in-vitro studies followed by IND application for clinical trial P1